According to this hypothesis, it has been shown that the botulinum toxin type A (BTA), which molecularly binds to SV2A (36), can inhibit the growth of SV2A-expressing LNCaP prostate cancer cells, both in vitro and in vivo (37). Here, SV2A is linked to prostate carcinoma.